Avior Wealth Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Avior Wealth Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-630	Closed	-$80K	–	829
2019 Q3	$80K	Hold	630	–	–	0.01%	431
2019 Q2	$90K	Sell	630 -370	-37%	-$49.7K	0.02%	417
2019 Q1	$142K	Sell	1,000 -1,744	-64%	-$227K	0.03%	378
2018 Q4	$340K	Buy	2,744 +30	+1%	+$4.45K	0.08%	225
2018 Q3	$456K	Buy	2,714 +575	+27%	+$98.9K	0.1%	197
2018 Q2	$369K	Buy	2,139 +470	+28%	+$76.8K	0.08%	215
2018 Q1	$252K	Sell	1,669 -340	-17%	-$49.9K	0.06%	261
2017 Q4	$271K	Buy	+2,009	New	+$279K	0.06%	263

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Avior Wealth Management's JAZZ Position: Q4 2019 in Review

Avior Wealth Management sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2019, closing a stake of 630 shares — an estimated $80K sold.

Avior Wealth Management first reported a position in JAZZ in Q4 2017 and held it in 8 quarters. The position peaked at $456K in Q3 2018. 446 funds tracked by Wall St. Rank hold JAZZ as of Q4 2019.

Avior Wealth Management reported no remaining Jazz Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Avior Wealth Management sold 630 Jazz Pharmaceuticals shares in Q4 2019, an estimated $80K.
Avior Wealth Management first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 8 quarters.
Avior Wealth Management's Jazz Pharmaceuticals position peaked at $456K in Q3 2018.
446 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2019.

Based on Avior Wealth Management's 13F filing for Q4 2019, filed 11 Feb 2020.